| DENALI THERAPEUTICS |
| USA |
| Gesundheit |
| US24823R1059 / A2H9G8 |
| 4DN (Frankfurt) / DNLI (NASDAQ) |
| FRA:4DN, ETR:4DN, 4DN:GR, NASDAQ:DNLI |
| - |
| https://denalitherapeutic.. |
|
Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing medicines for serious neurodegenerative and lysosomal storage diseases. Denali Therapeutics advances a portfolio of therapeutic programs aimed at conditions..
>Volltext.. |
| 3209.6 Mio. EUR |
| 2620.23 Mio. EUR |
| 3.11 Mio. EUR |
| -455.46 Mio. EUR |
| -441.41 Mio. EUR |
| -2.45 EUR |
| 32.53 Mio. EUR |
| 173.93 Mio. EUR |
| -374.6 Mio. EUR |
| 7.89 |
| - |
| -10.13% |
| - |
| - |
| - |
| DENALI THERAPEUTICS, DENALI THERAPEUTIC |
| 05.09.26 |
|